Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2011

Note 2 — Summary of Significant Accounting Policies [Abstract]



Entity	Percentage of Ownership	Location
NeoStem, Inc.	Parent Company	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
NeoStem (China) Inc. (1)	100%	People’s Republic of China
Qingdao Niao Bio-Technology Ltd.* (1)		People’s Republic of China
Beijing Ruijiao Bio-Technology Ltd.* (1)		People’s Republic of China
Tianjin Niou Bio-Technology Co., Ltd.* (1)		People’s Republic of China
CBH Acquisition LLC	100%	United States of America
China Biopharmaceuticals Holdings, Inc. (CBH)	100% owned by CBH Acquisition LLC	United States of America
Suzhou Erye Pharmaceuticals Company Ltd. (2)	51% owned by CBH	People’s Republic of China
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100% owned by PCT	United States of America
Athelos Corporation	80.1% owned by PCT	United States of America
PCT Allendale, LLC	100% owned by PCT	United States of America

Property, Plant and Equipment [Table Text Block]



	Useful Life	December 31, 2011			December 31, 2010

Building and improvements	25-30 years	$	9,874.0		$	—
Machinery and equipment	8-12 years	17.9			—
Lab equipment	5-7 years	1,559.1			365.8
Furniture and fixtures	5-12 years	632.4			274.3
Software	3-5 years	98.3			99.6
Leasehold improvements	2-3 years	702.0			64.9
Property, plant and equipment, Gross		12,883.6			804.6
Accumulated depreciation		(1,267.6		)	(369.1		)
Property, plant and equipment, Net		$	11,616.1		$	435.5

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]



	December 31,
	2011	2010
Stock Options	17,143,505	13,032,214
Warrants	37,389,825	21,843,507
Series E Preferred Stock, Common stock equivalents	3,989,669	5,289,948
Restricted Shares	976,668	51,666

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]



	December 31, 2011
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Money market investments	$	2,497.4	$	—	$	—
Embedded derivative liabilities	—		—		391.7
Warrant derivative liabilities	—		—		82.7
Contingent consideration	—		—		3,130.0



	December 31, 2010
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Money market investments	$	—	$	2,501.0	$	—
Embedded derivative liabilities	—		—		2,281.8
Warrant derivative liabilities	—		—		289.6

Schedue of finacial instrument activity [Table Text Block]



	Embedded Derivatives			Warrants
Beginning liability balance, December 31, 2009	$	—		$	36.0
Convertible redeemable Series E preferred stock and warrants issued	2,131.1			266.0
Change in fair value recorded in earnings	150.7			(12.4		)
Ending liability balance, December 31, 2010	$	2,281.8		$	289.6
Change in fair value recorded in earnings	(1,890.1		)	(206.9		)
Ending liability balance, December 31, 2011	$	391.7		$	82.7

- Definition

Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References+ Details